早期乳腺癌芳香化酶抑制剂引起骨关节疼痛相关研究进展
Research Progress on Aromatase Inhibitors Causing Arthralgia in Early Breast Cancer
摘要: 芳香化酶抑制剂(Aromatase Inhibitors, AIs)药物治疗绝经后早期乳腺癌引起的不良反应，影响了患者的日常生活，最常见的就是骨关节疼痛和骨骼肌僵硬，简称为(AI-associated arthralgia, AIA)或AIs诱发的肌肉骨骼综合征(AI-associated musculoskeletal symptoms, AIMSS)，AIA涉及多种临床因素和治疗方法，但是目前缺乏对AIA的统一定义及有效的评估工具，AIA没有得到最佳的管理与控制；有研究发现遗传基因变异也可能影响药物的疗效或毒性，目前越来越多的研究致力于寻找遗传生物标志物以改善风险预测、诊断和治疗。本文从AIA临床危险因素、治疗方法和其相关的单核苷酸多态性(Single Nucleotide Polymorphisms, SNP)几个方面出发，叙述了AIA相关研究进展，在帮助医生平衡内分泌治疗、提高患者依从性方面有重大意义。
Abstract: Adverse reactions caused by drug treatment of early postmenopausal breast cancer, Aromatase In-hibitors (AIs), affect the daily life of patients; the most common is bone joint pain and skeletal mus-cle stiffness, referred to as AI-Associated Arthralgia (AIA), or AI-Associated Musculoskeletal Symp-toms (AIMSS). AIA involves a variety of clinical factors and treatments, but currently there is a lack of a unified definition and effective assessment tools for AIA. AIA was not optimally managed and controlled; Some studies have found that genetic variations may also affect the efficacy or toxicity of drugs, and more and more research is focused on finding genetic biomarkers to improve risk pre-diction, diagnosis and treatment. In this paper, the clinical risk factors, therapeutic methods and Single Nucleotide Polymorphisms (SNP) associated with AIA are reviewed, which is of great signifi-cance in helping doctors balance endocrine therapy and improving patient compliance.
文章引用：晏婷婷, 王淼舟. 早期乳腺癌芳香化酶抑制剂引起骨关节疼痛相关研究进展[J]. 临床医学进展, 2022, 12(6): 5024-5031. https://doi.org/10.12677/ACM.2022.126729

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Harbeck, N. and Gnant, M. (2017) Breast Cancer. The Lancet, 389, 1134-1150. [Google Scholar] [CrossRef] 
[3] Van Asten, K., Neven, P., Lintermans, A., et al. (2014) Aromatase Inhibitors in the Breast Cancer Clinic: Focus on Exemestane. Endocrine-Related Cancer, 21, R31-R49. [Google Scholar] [CrossRef] 
[4] Condorelli, R. and Vaz-Luis, I. (2018) Managing Side Effects in Adju-vant Endocrine Therapy for Breast Cancer. Expert Review of Anticancer Therapy, 18, 1101-1112. [Google Scholar] [CrossRef] [PubMed]
[5] Auton, A., Brooks, L.D., et al. (2015) A Global Reference for Human Genetic Variation. Nature, 526, 68-74. [Google Scholar] [CrossRef] [PubMed]
[6] Blok, E.J., Derks, M.G., Van Der Hoeven, J.J., et al. (2015) Extended Adjuvant Endocrine Therapy in Hormone-Receptor Positive Early Breast Cancer: Current and Future Evidence. Cancer Treatment Reviews, 41, 271-276. [Google Scholar] [CrossRef] [PubMed]
[7] Oesterreich, S., Henry, N.L., Kidwell, K.M., et al. (2015) Associa-tions between Genetic Variants and the Effect of Letrozole and Exemestane on Bone Mass and Bone Turnover. Breast Cancer Research and Treatment, 154, 263-273. [Google Scholar] [CrossRef] [PubMed]
[8] Ingle, J.N., Schaid, D.J., Goss, P.E., et al. (2010) Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase In-hibitors. Journal of Clinical Oncology, 28, 4674-4682. [Google Scholar] [CrossRef] 
[9] Wang, J., Lu, K., Song, Y., et al. (2015) RANKL and OPG Poly-morphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients. PLoS ONE, 10, e0133964. [Google Scholar] [CrossRef] [PubMed]
[10] Coates, A.S., Keshaviah, A., Thurlimann, B., et al. (2007) Five Years of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endo-crine-Responsive Early Breast Cancer: Update of Study BIG 1-98. Journal of Clinical Oncology, 25, 486-492. [Google Scholar] [CrossRef] 
[11] Arimidex, T., et al. (2008) Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-Month Analysis of the ATAC Trial. The Lancet Oncology, 9, 45-53. [Google Scholar] [CrossRef] 
[12] Coombes, R.C., Kilburn, L.S., Snowdon, C.F., et al. (2007) Survival and Safety of Exemestane versus Tamoxifen after 2-3 Years’ Tamoxifen Treatment (Intergroup Exemestane Study): A Randomised Controlled Trial. The Lancet, 369, 559-570. [Google Scholar] [CrossRef] 
[13] Mao, J.J., Stricker, C., Bruner, D., et al. (2009) Patterns and Risk Factors Associated with Aromatase Inhibitor-Related Arthralgia among Breast Cancer Survivors. Cancer, 115, 3631-3639. [Google Scholar] [CrossRef] [PubMed]
[14] Crew, K.D., Greenlee, H., Capodice, J., et al. (2007) Preva-lence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. Journal of Clinical Oncology, 25, 3877-3883. [Google Scholar] [CrossRef] 
[15] Mao, J.J., Su, H.I., Feng, R., et al. (2011) Association of Func-tional Polymorphisms in CYP19A1 with Aromatase Inhibitor Associated Arthralgia in Breast Cancer Survivors. Breast Cancer Research, 13, R8. [Google Scholar] [CrossRef] [PubMed]
[16] Niravath, P. (2013) Aromatase Inhibitor-Induced Arthralgia: A Review. An-nals of Oncology, 24, 1443-1449. [Google Scholar] [CrossRef] [PubMed]
[17] Tenti, S., Correale, P., Cheleschi, S., et al. (2020) Aromatase Inhibi-tors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. International Journal of Molecular Sciences, 21, 5625. [Google Scholar] [CrossRef] [PubMed]
[18] Swenson, K.K., Nissen, M.J., Henly, S.J., et al. (2013) Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women with Breast Cancer Re-ceiving Aromatase Inhibitors. Oncology Nursing Forum, 40, 549-557. [Google Scholar] [CrossRef] 
[19] Roberts, K., Rickett, K., Greer, R., et al. (2017) Management of Aromatase Inhibitor Induced Musculoskeletal Symptoms in Postmenopausal Early Breast Cancer: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 111, 66-80. [Google Scholar] [CrossRef] [PubMed]
[20] Sestak, I., Cuzick, J., Sapunar, F., et al. (2008) Risk Factors for Joint Symptoms in Patients Enrolled in the ATAC Trial: A Retrospective, Exploratory Analysis. The Lancet Oncolo-gy, 9, 866-872. [Google Scholar] [CrossRef] 
[21] Lombard, J.M., Zdenkowski, N., Wells, K., et al. (2016) Aromatase Inhibitor Induced Musculoskeletal Syndrome: A Significant Problem with Limited Treatment Options. Sup-portive Care in Cancer, 24, 2139-2146. [Google Scholar] [CrossRef] [PubMed]
[22] Kanematsu, M., Morimoto, M., Honda, J., et al. (2011) The Time since Last Menstrual Period Is Important as a Clinical Predictor for Non-Steroidal Aromatase Inhibitor-Related Arthralgia. BMC Cancer, 11, Article No. 436. [Google Scholar] [CrossRef] [PubMed]
[23] 于新颖, 文翠菊, 孙红娟, 等. 内分泌治疗绝经乳腺癌患者骨关节疼痛及其相关影响因素分析[J]. 中国实用医药, 2018, 13(32): 69-71.
[24] Henry, N.L., Azzouz, F., Desta, Z., et al. (2012) Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Ear-ly-Stage Breast Cancer. Journal of Clinical Oncology, 30, 936-942. [Google Scholar] [CrossRef] 
[25] Crew, K.D., Capodice, J.L., Greenlee, H., et al. (2010) Random-ized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women with Early-Stage Breast Cancer. Journal of Clinical Oncology, 28, 1154-1160. [Google Scholar] [CrossRef] 
[26] Santa-Maria, C.A., Bardia, A., Blackford, A.L., et al. (2018) A Phase II Study Evaluating the Efficacy of Zoledronic Acid in Prevention of Aromatase Inhibitor-Associated Musculo-skeletal Symptoms: The ZAP Trial. Breast Cancer Research and Treatment, 171, 121-129. [Google Scholar] [CrossRef] [PubMed]
[27] Auton, A., Brooks, L.D., Durbin, R.M., et al. (2015) A Global Reference for Human Genetic Variation. Nature, 526, 68-74. [Google Scholar] [CrossRef] [PubMed]
[28] Michailidou, K., Beesley, J., Lindstrom, S., et al. (2015) Genome-Wide Association Analysis of More than 120,000 Individuals Iden-tifies 15 New Susceptibility Loci for Breast Cancer. Nature Genetics, 47, 373-380. [Google Scholar] [CrossRef] [PubMed]
[29] 常培叶, 赵平. 单核苷酸多态性检测方法研究进展[J]. 中国老年学杂志, 2015, 35(16): 4720-4722.
[30] 杨春晓, 张玉, 师少军. SNP基因分型检测技术及应用进展[J]. 中国药师, 2013, 16(6): 811-816.
[31] Gervasini, G., Jara, C., Olier, C., et al. (2017) Polymorphisms in ABCB1 and CYP19A1 Genes Affect Anastrozole Plasma Concentrations and Clinical Outcomes in Postmenopausal Breast Cancer Patients. British Journal of Clinical Pharmacology, 83, 562-571. [Google Scholar] [CrossRef] [PubMed]
[32] Park, I.H., Lee, Y.S., Lee, K.S., et al. (2011) Single Nucleotide Polymorphisms of CYP19A1 Predict Clinical Outcomes and Adverse Events Asso-ciated with Letrozole in Patients with Metastatic Breast Cancer. Cancer Chemotherapy and Pharmacology, 68, 1263-1271. [Google Scholar] [CrossRef] [PubMed]
[33] Fontein, D.B., Houtsma, D., Nortier, J.W., et al. (2014) Germline Variants in the CYP19A1 Gene Are Related to Specific Adverse Events in Aromatase Inhibitor Users: A Substudy of Dutch Patients in the TEAM Trial. Breast Cancer Research and Treatment, 144, 599-606. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, J., Lu, K., Song, Y., et al. (2013) Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer. PLoS ONE, 8, e68798. [Google Scholar] [CrossRef] [PubMed]
[35] Henry, N.L., Skaar, T.C., Dantzer, J., et al. (2013) Genetic As-sociations with Toxicity-Related Discontinuation of Aromatase Inhibitor Therapy for Breast Cancer. Breast Cancer Re-search and Treatment, 138, 807-816. [Google Scholar] [CrossRef] [PubMed]
[36] Lintermans, A., Van Asten, K., Jongen, L., et al. (2016) Genetic Variant in the Osteoprotegerin Gene Is Associated with Aromatase Inhibitor-Related Musculoskeletal Toxicity in Breast Cancer Patients. European Journal of Cancer, 56, 31-36. [Google Scholar] [CrossRef] [PubMed]
[37] Garcia-Giralt, N., Rodriguez-Sanz, M., Prieto-Alhambra, D., et al. (2013) Genetic Determinants of Aromatase Inhibitor-Related Arthralgia: The B-ABLE Cohort Study. Breast Cancer Re-search and Treatment, 140, 385-395. [Google Scholar] [CrossRef] [PubMed]
[38] Romero, S.A.D., Su, H.I., Satagopan, J., et al. (2020) Clinical and Genetic Risk Factors for Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors. Breast, 49, 48-54. [Google Scholar] [CrossRef] [PubMed]
[39] Simonsson, M., Veerla, S., Markkula, A., et al. (2016) CYP1A2—A Novel Genetic Marker for Early Aromatase Inhibitor Response in the Treatment of Breast Cancer Patients. BMC Cancer, 16, Article No. 256. [Google Scholar] [CrossRef] [PubMed]

为你推荐